Heritage Introduces Nimodipine Soft Gel Capsules
Heritage Pharmaceuticals announced the immediate availability of Nimodipine Soft Gelatin Capsules in 30 mg strength. Heritage's development and manufacturing partner, Banner Pharmacaps Inc., received final approval of its Abbreviated New Drug Application (ANDA) for an AB Rated equivalent of Nimotop on January 17, 2008.
Nimodipine Soft Gel Capsules are the generic equivalent of Nimotop Capsules marketed by Bayer. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage.
Nimodipine had U.S. brand and generic sales of approximately $30 million for the 12-month period ending Dec. 31, 2007 according to IMS Health.
Commenting on the launch, Heritage President & CEO, Jeffrey Glazer, stated, "The launch of Nimodipine represents the first of several soft gelatin capsule generic products from our partnership with Banner. This product will enable Heritage's sales team to begin supplying the Institutional/Hospital class of trade and broadens our national account coverage. In addition, Nimodipine expands our niche, high-value product offerings as we continue to grow our global portfolio."